BAUSSS生物标志物改善黑色素瘤生存风险评估
该文介绍BAUSSS生物标志物算法,整合Breslow厚度、年龄、溃疡、亚型、性别和部位六项特征预测原发性皮肤黑色素瘤患者生存风险。BAUSSS比AJCC分期更准确且成本更低,无需额外手术或检查,可辅助识别适合辅助药物治疗的高危患者,并已提供免费单页工具供临床使用。
要点
- BAUSSS算法基于六项临床与病理特征预测黑色素瘤死亡风险。
- BAUSSS比AJCC分期更准确、成本更低,且无需额外手术或检查。
- 单页BAUSSS生存图表可免费下载,便于医患面对面沟通预后。
核心结论
- BAUSSS生物标志物算法预测黑色素瘤生存风险比AJCC分期更准确且成本更低。
研究设计与样本
- 从多种数据来源开发BAUSSS算法,整合Breslow厚度、年龄、溃疡、亚型、性别和部位六项特征预测死亡风险。
主要发现
- BAUSSS方法确定黑色素瘤预后比AJCC分期系统更准确且成本更低。
- 该方法仅需原发肿瘤广泛局部切除,无需前哨淋巴结活检等额外手术、费用、住院、检查或麻醉。
- BAUSSS可辅助识别风险足够高、可考虑辅助药物治疗的原发性黑色素瘤患者。
临床怎么用
- 鼓励临床医生下载并彩色打印单页BAUSSS死亡预测工具,覆膜后与患者面对面咨询使用。
- 患者可借此了解自身长期预后,并与他人比较肿瘤严重程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The American Joint Committee on Cancer (AJCC) method of staging melanoma is dated and inaccurate. It ignores important prognostic melanoma features, especially the patient's age. BAUSSS is more accurate in determining survival risk for primary cutaneous melanoma patients who have no clinical or imaging evidence of nodal or distant metastases. BAUSSS is an algorithm incorporating analysis of Breslow thickness, Age, Ulceration, Subtype of melanoma, Sex and Site. These are the six features from the patient history along with the details from the melanoma pathology report that are most predictive of mortality outcome. OBJECTIVE: To develop a single-page document that allows the clinician to determine BAUSSS biomarker-predicted prognosis in consultation with the patient. METHOD: From various data sources, we developed an algorithm to predict melanoma mortality using the BAUSSS biomarker system. The single-page algorithm was made available to download at https://globalmelanoma.net/bausss-survival-chart, thus being readily available without charge to all clinicians and their patients. RESULTS: BAUSSS method of determining melanoma prognosis is more accurate and less costly than the AJCC staging system. The only surgery the patient requires is wide local excision of the primary tumour. This method of ascertaining melanoma risk does not require added surgery, costs, hospitalization, tests and anaesthesia, such as would be required if sentinel lymph node biopsy was undertaken. BAUSSS can be a useful tool in determining which primary melanoma patients are at sufficiently high risk to be considered for adjuvant drug therapy. CONCLUSIONS: We encourage clinicians to download and print in colour this single-page BAUSSS mortality prediction tool, laminate it, and use it face to face with the patient in consultations. Not only will the patient be able to recognize his/her long-term prognosis but will also be able to see how their tumour severity compares with others.
引用
- Dixon AJ, Steinman HK, Nirenberg A, et al. BAUSSS biomarker improves melanoma survival risk assessment. J Eur Acad Dermatol Venereol. 2024. PMID: 39215563. doi:10.1111/jdv.20292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。